Q32 Bio Inc. (QTTB) EBITDA Margin (2018 - 2023)

Q32 Bio has reported EBITDA Margin for 6 years, with the latest figure at 1897.72% in Q4 2023.

• On a quarterly basis, EBITDA Margin rose 619872.0% year-over-year to 1897.72% in Q4 2023; TTM through Sep 2024 was 5690.07%, a 633616.0% increase from a year earlier, with the FY2025 full-year figure at 31.45%, changed N/A from the prior year.
• EBITDA Margin was 1897.72% for Q4 2023 at Q32 Bio, up from 419.47% in the prior quarter.
• The five-year high for EBITDA Margin was 1897.72% in Q4 2023, with the low at 9304.81% in Q1 2019.
• Average EBITDA Margin over 5 years is 3582.2%, with a median of 4145.07% recorded in 2021.
• The sharpest annual moves came in 2019 and 2021: EBITDA Margin plunged 835743 bps in 2019, then surged 620233 bps in 2021.
• Over 5 years, EBITDA Margin stood at 4539.79% in 2019, then jumped by 33 bps to 3041.02% in 2020, then slumped by 38 bps to 4192.64% in 2021, then slipped by 3 bps to 4301.0% in 2022, then jumped by 144 bps to 1897.72% in 2023.
• The last three EBITDA Margin figures came in at 1897.72% (Q4 2023), 419.47% (Q3 2023), and 226.99% (Q2 2023), per Business Quant data.